HIGHLIGHTS
- who: Fei Ren from the (UNIVERSITY) have published the research: Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report, in the Journal: (JOURNAL)
- what: The authors reported a patient with lung adenocarcinoma who developed pseudoprogression in osimertinib maintenance after definitive chemoradiation.
SUMMARY
At present, immune checkpoint inhibitors and targeted drugs have become widely used in locally advanced non-small cell lung cancer (NSCLC). Two case reports showed three ALK-positive NSCLC patients who developed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.